



# Expression patterns and prognostic value of programmed death ligand-1 and programmed death 1 in thymoma and thymic carcinoma

Ikuro Sekine, Yuka Aida, Hideo Suzuki

Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

*Correspondence to:* Ikuro Sekine. Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan. Email: isekine@md.tsukuba.ac.jp.

*Provenance:* This is an invited Editorial commissioned by Section Editor Dr. Zhuoqi Jia (Thoracic Department, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China).

*Comment on:* Owen D, Chu B, Lehman AM, *et al.* Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. *J Thorac Oncol* 2018;13:1204-12.

Received: 28 June 2018; Accepted: 10 August 2018; Published: 11 September 2018.

doi: 10.21037/med.2018.08.04

View this article at: <http://dx.doi.org/10.21037/med.2018.08.04>

Thymic epithelial tumors (TETs) arising in the anterior mediastinum are rare malignancies that account for less than 1% of all adult cancers (1). The incidence of TETs is 1.5 to 3.2 per 1,000,000 person-years (2,3). The International Thymic Malignancy Interest Group database including more than 6,000 patients showed that thymoma and thymic carcinoma accounted for 81% and 14%, respectively, of all TETs (4). Of these, 63%, 23%, and 13% of patients had local (stage I–II), locally advanced (stage III), and disseminated or distant metastatic (stage IV) disease, respectively (4). These figures are consistent with those from population-based studies (2,5).

Complete resection is the curative treatment that assures long-term survival in patients with resectable disease, whereas for patients with disseminated disease or distant metastases systemic chemotherapy is the mainstay of treatment. A combination of carboplatin plus paclitaxel has been used widely, but the response rate and median progression-free survival (PFS) are 43% and 16.7 months, respectively, in patients with advanced thymoma and 22% to 36% and 5 to 7.5 months, respectively, in patients with thymic carcinoma (6,7).

The limitation of conventional chemotherapy has prompted medical oncologists to develop molecular targeted therapies in patients with advanced TET. Recently, early results of phase II trials of antibody therapies that target programmed death 1 (PD-1) were reported. Phase II

trials of pembrolizumab in patients with recurrent thymic carcinoma who had progressed after at least one line of chemotherapy showed an objective response in about 20% of patients and stable disease in more than half of patients with a median PFS of 4 to 6 months (8,9). In contrast, a phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma with progression after at least one previous platinum-based chemotherapy found no objective response in 15 patients for the first stage with a median PFS of 3.8 [95% confidence interval (CI), 1.9–5.6] months, resulting in early termination of accrual to this study (10). This discrepancy among the trials, as well as among patients, can be explained by the heterogeneity of thymic carcinoma among patients, which should be assessed by adequate biomarkers. Programmed death ligand-1 (PD-L1) expression on tumor cells and PD-1 expression on tumor-infiltrating lymphocytes (TILs) are candidates for such a biomarker, because an association between these markers and survival has been observed in some tumor types (11).

Owen *et al.* investigated the expression patterns of PD-L1 and PD-1 and their association with clinical and pathological parameters in thymoma and thymic carcinoma (12). They assessed PD-L1 and PD-1 expression by immunohistochemistry using anti-PD-L1 antibody (22C3) and anti-PD-1 antibody (NAT105) and graded the expression in a semi quantitative 0–5 scoring system

**Table 1** PD-L1 expression in thymoma and thymic cancer

Study No.	Authors, year	Anti-PD-L1 antibody	Definition of PD-L1 positivity	No. of patients		PD-L1 positivity in tumor cells, n (%)		Association of PD-L1 expression with		
				Thymoma	Thymic cancer	Thymoma	Thymic cancer	Tumor stage	EFS	OS
1	Brown <i>et al.</i> , 2003	29E.2A3; 29E.5A9	Not defined	26	8	21 [81]	7 [88]	NA	NA	NA
2	Katsuya <i>et al.</i> , 2015	E1L3N	H-score $\geq 1$	102	37	22 [23]	26 [70]	No	NA	No
3	Padda <i>et al.</i> , 2015	Sino biological A clone 15	semiquantitative scoring system (0-3) =3	65	4	44 [68]	3 [75]	A trend for early stage (P=0.056)	A trend for poor EFS (P=0.064)	Poor OS (P=0.035)
4	Yokoyama <i>et al.</i> , 2016	EPR1161	PD-L1-positive rate $\geq 38\%$	82	0	44 [54]	NA	Advanced stage (P=0.019)	Poor DFS (P=0.021)	No
5	Yokoyama <i>et al.</i> , 2016	EPR1161	H-score $>20$	0	25	NA	20 [80]	No	Better DFS (P=0.004)	Better OS (P=0.010)
6	Katsuya <i>et al.</i> , 2016	E1L3N	H-score $\geq 1$	9	17	6 [67]	7 [41]	NA	NA	No
7	Marchevsky and Walts, 2017	SP142	% of positive tumor cells $\geq 1\%$	38	8	35 [92]	4 [50]	NA	NA	NA
8	Weissferdt <i>et al.</i> , 2017	EPR4877	% of positive tumor cells $\geq 5\%$	74	26	16 [22]	13 [50]	No	NA	No
9	Tiseo <i>et al.</i> , 2017	E1L3N	H-score $\geq 1$	87	20	16 [18]	13 [65]	Advanced stage (P=0.010)	NA	No
10	Arbour <i>et al.</i> , 2017	E1L3N	% of positive tumor cells $>25\%$	12	11	11 [92]	4 [36]	No	NA	Better OS (P=0.02)
11	Chen <i>et al.</i> , 2017	SP142	H-score $>3$	50	20	24 [48]	14 [70]	Advanced stage (P=0.004)	NA	NA
12	Marchevsky <i>et al.</i> , 2017	SP142	% of positive tumor cells $\geq 1\%$	38	8	35 [92]	4 [50]	NA	NA	NA
13	Guleria <i>et al.</i> , 2018	SP263	% of positive tumor cells $\geq 25\%$	84	0	69 [82]	NA	No	NA	NA
14	Bagir <i>et al.</i> , 2018	AM26531AF-N	% of positive tumor cells $>5\%$	38	6	31 [82]	5 [83]	No	NA	No
15	Sakane <i>et al.</i> , 2018	SP142, SP263, 22C3, and 28-8	% of positive tumor cells $>50\%$	0	53	NA	[41-54]	No	NA	Better OS (P=0.025) by 22C3
16	Owen <i>et al.</i> , 2018	22C3	A semiquantitative scoring system (0-5) $\geq 1$	32	3	26 [81]	3 [100]	No	NA	No

NA, not available; OS, overall survival; PD-1, programmed death 1; PDL-1, programmed death ligand-1; EFS, event-free survival; DFS, disease-free survival.

**Table 2** PD-1 expression in thymoma and thymic cancer

Study No.	Authors, year	Anti-PD-1 antibody	Definition of PD-1 positivity	No. of patients		Tumor stage	PD-1 positivity in TILs, n (%)		Association of PD-1 expression with	
				Thymoma	Thymic cancer		Thymoma	Thymic cancer	Tumor stage	OS
5	Yokoyama et al., 2016	NAT105	The mean number of TILs with positive staining	0	25	I-II: 28%; III: 36%; IV: 36%	NA	NA	NA	Poor survival (P=0.034)
6	Katsuya et al., 2016	NAT105	A semiquantitative scoring system (0-3) ≥1 in TILs	9	17	III: 6%; IV: 77%; relapse: 17%	4 [44]	8 [47]	NA	No
8	Weissferdt et al., 2017	EPR4877	% of positive cells ≥5% in TILs	74	26	I-II: 51%; III: 28%; IV: 22%	46 [62]	6 [23]	Higher stage in thymic carcinoma (P=0.01)	No
10	Arbour et al., 2017	NAT105	A semiquantitative scoring system (0-3) ≥1 in TILs	12	11	I-II: 26%; III: 26%; IV: 48%	10 [83]	6 [55]	NA	NA
11	Chen et al., 2017	NAT	% of positive cells ≥5% in interstitial lymphocytes	50	20	I-II: 51%; III: 29%; IV: 20%	NA	13 [65]	NA	NA
14	Bagir et al., 2018	MRQ-22	% of positive cells >5% in microenvironment	38	6	I-II: 55%; III: 7%; IV: 16%	4 [11]	2 [33]	No	No
16	Owen et al., 2018	NAT105	A semiquantitative scoring system (0-5) ≥1 in TILs	32	3	I-II: 57%; III: 20%; IV: 20%; NA: 3%	26 [81]	1 [33]	No	No

TILs, tumor infiltrating immune cells; TILs, tumor infiltrating lymphocytes; NA, not available; OS, overall survival; PD-1, programmed death 1.

(0= no expression; 1= rare; 2= low; 3= moderate; 4= high; and 5= very high). PD-L1 expression (score  $\geq 1$ ) was detected in 81% (26/32) of thymoma and 100% (3/3) of thymic carcinoma samples. PD-1 expression was noted in 81% of thymoma and 33% of thymic carcinoma samples. Multiple slides prepared from the same tumor specimen in three patients with thymoma demonstrated intra-tumoral heterogeneity in terms of PD-L1 and PD-1 expression. Inconsistent with results from previous papers, neither the PD-L1 expression nor the PD-1 expression was associated with the pathological WHO grade, tumor stage, or overall survival.

PD-L1 expression in tumor cells varies in the literature with studies showing expression from 23% to 92% in thymoma and 36% to 100% in thymic carcinoma (Table 1). When comparing the PD-L1 expression between thymoma and thymic carcinoma within a single study, some studies showed that PD-L1 expression was higher in thymoma than in thymic carcinoma, but others showed that PD-L1 expression was higher in thymic carcinoma than in thymoma. Its association with tumor stage was also inconsistent between studies; PD-L1 expression was associated with advanced stage or early stage in some studies, but most studies showed no association with tumor stage.

How can we explain these discrepant results? They may be attributable to the different PD-L1 immunohistochemical assays used in each study (Table 1). In a comparison of four PD-L1 assays with different antibodies (SP142, SP263, 22C3, and 28-8), as high as 47% of cases showed discordance between PD-L1 expression levels (13). The assessment method of PD-L1 expression and definition of PD-L1 positivity also varies among studies. A semiquantitative scoring system was used in two studies, a percentage of positive tumor cells in six studies, a percentage of the PD-L1—positive area/cytokeratin-positive area in one study, and H-score in five studies. Considering the intratumoral heterogeneity of PD-L1 expression, H-score may be better than the other methods, but it was used in less than one-third of studies. The cutoff value of PD-L1 positivity is also not uniform. The threshold for PD-L1 positivity ranged from 1% to 50% when examining the percentage of positive tumor cells and from 1 to 20 when using the H-score.

Interpretation of PD-1 expression in TILs is more complicated, because identification of TILs is difficult. No studies used multiplex immunohistochemistry with antibodies for T-lymphocyte identification. In addition, methods for evaluating the PD-1 expression also vary

between studies, as with PD-L1 expression (Table 2).

The association of PD-L1 and PD-1 expression with survival is also conflicting (Tables 1,2). It is difficult to assess the prognostic value of PD-L1 and PD-1 expression in these studies, because established prognostic factors, including the pathological WHO grade and tumor staging system of TETs, were not controlled. Small sample size was also an issue.

In conclusion, establishing biomarkers to select eligible patients for PD-1/PD-L1 pathway inhibitors is an immediate need in the treatment of advanced TETs. PD-L1 expression on tumor cells and PD-1 expression on TILs are clearly candidates for this purpose, but recently obtained clinical data are not sufficient to support their use as biomarkers. A PD-1/PD-L1 immunohistochemical assay with an optimal antibody, an assessment method of staining, and definition of positivity should be standardized in future clinical studies.

### Acknowledgements

We would like to thank Editage ([www.editage.jp](http://www.editage.jp)) for English language editing.

### Footnote

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

### References

1. Travis WD, Brambilla E, Burke AP, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. France, Lyon: IARC, 2004.
2. de Jong WK, Blaauwgeers JL, Schaapveld M, et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. *Eur J Cancer* 2008;44:123-30.
3. Siesling S, van der Zwan JM, Izarzugaza I, et al. Rare thoracic cancers, including peritoneum mesothelioma. *Eur J Cancer* 2012;48:949-60.
4. Huang J, Ahmad U, Antonicelli A, et al. Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors. *J Thorac Oncol* 2014;9:1573-8.
5. Mariano C, Ionescu DN, Cheung WY, et al. Thymoma: a population-based study of the management and outcomes

- for the province of British Columbia. *J Thorac Oncol* 2013;8:109-17.
6. Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. *J Clin Oncol* 2011;29:2060-5.
  7. Hirai F, Yamanaka T, Taguchi K, et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. *Ann Oncol* 2015;26:363-8.
  8. Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. *Lancet Oncol* 2018;19:347-55.
  9. Cho J, Kim HS, Ku BM, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. *J Clin Oncol* 2018;JCO2017773184.
  10. Seto T, Katsuya Y, Horinouchi H, et al. Primary result of an investigator-initiated phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study (NCCH1505). *J Thorac Oncol* 2018;13:S61-2.
  11. Zhang Y, Kang S, Shen J, et al. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) Expression in epithelial-originated cancer: a meta-analysis. *Medicine (Baltimore)* 2015;94:e515.
  12. Owen D, Chu B, Lehman AM, et al. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. *J Thorac Oncol* 2018;13:1204-12.
  13. Sakane T, Murase T, Okuda K, et al. A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. *Oncotarget* 2018;9:6993-7009.

doi: 10.21037/med.2018.08.04

**Cite this article as:** Sekine I, Aida Y, Suzuki H. Expression patterns and prognostic value of PD-L1 and PD-1 in thymoma and thymic carcinoma. *Mediastinum* 2018;2:54.